Herniation of the tuft with outgrowth of vessels through the glomerular entrance in diabetic nephropathy damages the juxtaglomerular apparatus

American Journal of Physiology - Renal Physiology

Volumn 317, Issue 2, 2019, Pages F399-F410

  Löwen, Jana ^a,b   Gröne, Elisabeth ^b   Gröne, Hermann Josef ^b,c   Kriz, Wilhelm ^a  

^a MEDICAL FACULTY MANNHEIM HEIDELBERG UNIVERSITY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Destruction of the juxtaglomerular apparatus; Diabetic nephropathy; Herniation of the glomerular tuft; Mesangial matrix accumulation; Outgrowth of glomerular vessels

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; MESSENGER RNA; VASCULOTROPIN A; ANGPT1 PROTEIN, HUMAN; ANGPT2 PROTEIN, HUMAN; KDR PROTEIN, HUMAN; TEK PROTEIN, HUMAN; VASCULOTROPIN RECEPTOR 2; VEGFA PROTEIN, HUMAN;

ARTERIOLE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; FEEDBACK SYSTEM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; JUXTAGLOMERULAR APPARATUS; KIDNEY BIOPSY; KIDNEY BLOOD VESSEL; MACULA DENSA; MESANGIUM; MRNA EXPRESSION LEVEL; PLASMA; PRIORITY JOURNAL; DISEASE EXACERBATION; GENETICS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; VASCULARIZATION;

ANGIOPOIETIN-1; ANGIOPOIETIN-2; ARTERIOLES; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; GLOMERULAR MESANGIUM; HUMANS; JUXTAGLOMERULAR APPARATUS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, TIE-2; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 85070495244     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00617.2018     Document Type: Article

References (33)

1. Anders HJ, Davis JM, Thurau K. Nephron protection in diabetic kidney disease. N Engl J Med 375: 2096–2098, 2016. doi:10.1056/NEJMcibr1608564.
2. Baelde HJ, Eikmans M, Doran PP, Lappin DW, de Heer E, Bruijn JA. Gene expression profiling in glomeruli from human kidneys with diabetic nephropathy. Am J Kidney Dis 43: 636–650, 2004. doi:10.1053/j.ajkd. 2003.12.028.
3. Baelde HJ, Eikmans M, Lappin DW, Doran PP, Hohenadel D, Brink-koetter PT, van der Woude FJ, Waldherr R, Rabelink TJ, de Heer E, Bruijn JA. Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss. Kidney Int 71: 637–645, 2007. doi:10.1038/sj.ki.5002101.
4. Cha DR, Kim NH, Yoon JW, Jo SK, Cho WY, Kim HK, Won NH. Role of vascular endothelial growth factor in diabetic nephropathy. Kidney Int Suppl 58: S104–S112, 2000. doi:10.1046/j.1523-1755.2000.07717.x.
5. Chen S, Li H, Zhang C, Li Z, Wang Q, Guo J, Luo C, Wang Y. Urinary angiopoietin-2 is associated with albuminuria in patients with type 2 diabetes mellitus. Int J Endocrinol 2015: 163120, 2015. doi:10.1155/2015/163120.
6. Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, Fagan NM, Woerle HJ, Johansen OE, Broedl UC, von Eynatten M. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129: 587–597, 2014. doi:10.1161/CIRCULATIONAHA.113.005081.
7. Dei Cas A, Gnudi L. VEGF and angiopoietins in diabetic glomerulopathy: how far for a new treatment? Metabolism 61: 1666–1673, 2012. doi:10.1016/j.metabol.2012.04.004.
8. Elger M, Sakai T, Kriz W. The vascular pole of the renal glomerulus of rat. Adv Anat Embryol Cell Biol 139: 1–98, 1998. doi:10.1007/978-3-642-80449-6_1.
9. Gnudi L. Angiopoietins and diabetic nephropathy. Diabetologia 59: 1616–1620, 2016. doi:10.1007/s00125-016-3995-3.
10. Gnudi L, Benedetti S, Woolf AS, Long DA. Vascular growth factors play critical roles in kidney glomeruli. Clin Sci (Lond) 129: 1225–1236, 2015. doi:10.1042/CS20150403.
11. Gröne HJ, Simon M, Gröne EF. Expression of vascular endothelial growth factor in renal vascular disease and renal allografts. J Pathol 177: 259–267, 1995. doi:10.1002/path.1711770308.
12. Hohenstein B, Hausknecht B, Boehmer K, Riess R, Brekken RA, Hugo CP. Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney Int 69: 1654–1661, 2006. doi:10.1038/sj.ki.5000294.
13. Isidori AM, Venneri MA, Fiore D. Angiopoietin-1 and angiopoietin-2 in metabolic disorders: therapeutic strategies to restore the highs and lows of angiogenesis in diabetes. J Endocrinol Invest 39: 1235–1246, 2016. doi:10.1007/s40618-016-0502-0.
14. Kalra S, Singh V, Nagrale D. Sodium-glucose cotransporter-2 inhibition and the glomerulus: a review. Adv Ther 33: 1502–1518, 2016. doi:10. 1007/s12325-016-0379-5.
15. Kanesaki Y, Suzuki D, Uehara G, Toyoda M, Katoh T, Sakai H, Watanabe T. Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy. Am J Kidney Dis 45: 288–294, 2005. doi:10.1053/j.ajkd.2004.09. 020.
16. Kriz W, Lemley KV. Mechanical challenges to the glomerular filtration barrier: adaptations and pathway to sclerosis. Pediatr Nephrol 32: 405– 417, 2017. doi:10.1007/s00467-016-3358-9.
17. Kriz W, Löwen J, Federico G, van den Born J, Gröne E, Gröne HJ. Accumulation of worn-out GBM material substantially contributes to mesangial matrix expansion in diabetic nephropathy. Am J Physiol Renal Physiol 312: F1101–F1111, 2017. doi:10.1152/ajprenal.00020.2017.
18. Lindenmeyer MT, Kretzler M, Boucherot A, Berra S, Yasuda Y, Henger A, Eichinger F, Gaiser S, Schmid H, Rastaldi MP, Schrier RW, Schlöndorff D, Cohen CD. Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy. JAm Soc Nephrol 18: 1765–1776, 2007. doi:10.1681/ASN.2006121304.
19. Min W, Yamanaka N. Three-dimensional analysis of increased vascula-ture around the glomerular vascular pole in diabetic nephropathy. Virchows Arch A Pathol Anat Histopathol 423: 201–207, 1993. doi:10.1007/BF01614771.
20. Nakagawa T, Sato W, Glushakova O, Heinig M, Clarke T, Campbell-Thompson M, Yuzawa Y, Atkinson MA, Johnson RJ, Croker B. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J Am Soc Nephrol 18: 539–550, 2007. doi:10.1681/ASN.2006050459.
21. Nakagawa T, Sato W, Kosugi T, Johnson RJ. Uncoupling of VEGF with endothelial NO as a potential mechanism for abnormal angiogenesis in the diabetic nephropathy. J Diabetes Res 2013: 184539, 2013. doi:10. 1155/2013/184539.
22. Østerby R, Asplund J, Bangstad HJ, Nyberg G, Rudberg S, Viberti GC, Walker JD. Neovascularization at the vascular pole region in diabetic glomerulopathy. Nephrol Dial Transplant 14: 348–352, 1999. doi:10.1093/ndt/14.2.348.
23. Østerby R, Hartmann A, Nyengaard JR, Bangstad HJ. Development of renal structural lesions in type-1 diabetic patients with microalbuminuria. Observations by light microscopy in 8-year follow-up biopsies. Virchows Arch 440: 94–101, 2002. doi:10.1007/s004280100485.
24. Østerby R, Nyberg G. New vessel formation in the renal corpuscles in advanced diabetic glomerulopathy. J Diabet Complications 1: 122–127, 1987. doi:10.1016/S0891-6632(87)80069-7.
25. Papapetropoulos A, García-Cardeña G, Dengler TJ, Maisonpierre PC, Yancopoulos GD, Sessa WC. Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab Invest 79: 213–223, 1999.
26. Porubsky S, Federico G, Müthing J, Jennemann R, Gretz N, Büttner S, Obermüller N, Jung O, Hauser IA, Gröne E, Geiger H, Gröne HJ, Betz C. Direct acute tubular damage contributes to Shigatoxin-mediated kidney failure. J Pathol 234: 120–133, 2014. doi:10.1002/path.4388.
27. Saharinen P, Eklund L, Alitalo K. Therapeutic targeting of the angio-poietin-TIE pathway. Nat Rev Drug Discov 16: 635–661, 2017. doi:10. 1038/nrd.2016.278.
28. Satchell SC, Harper SJ, Tooke JE, Kerjaschki D, Saleem MA, Mathieson PW. Human podocytes express angiopoietin 1, a potential regulator of glomerular vascular endothelial growth factor. J Am Soc Nephrol 13: 544–550, 2002.
29. Satchell SC, Mathieson PW. Angiopoietins: microvascular modulators with potential roles in glomerular pathophysiology. J Nephrol 16: 168– 178, 2003.
30. Vallon V, Richter K, Blantz RC, Thomson S, Osswald H. Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol 10: 2569–2576, 1999.
31. Witzenbichler B, Maisonpierre PC, Jones P, Yancopoulos GD, Isner JM. Chemotactic properties of angiopoietin-1 and-2, ligands for the endothelial-specific receptor tyrosine kinase Tie2. J Biol Chem 273: 18514–18521, 1998. doi:10.1074/jbc.273.29.18514.
32. Woolf AS, Gnudi L, Long DA. Roles of angiopoietins in kidney development and disease. J Am Soc Nephrol 20: 239–244, 2009. doi:10.1681/ASN.2008020243.
33. Woolf AS, Yuan HT. Angiopoietin growth factors and Tie receptor tyrosine kinases in renal vascular development. Pediatr Nephrol 16: 177–184, 2001. doi:10.1007/s004670000509.